Health Catalyst, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on February 16, 2024, by Health Catalyst, Inc. (HCAT), a provider of healthcare data analytics and technology solutions. The filing primarily addresses significant changes in executive leadership and board composition effective March 1, 2024. Additionally, the filing references the company's financial results for the quarter and year ended December 31, 2023, which were announced via press release on February 22, 2024.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained in the attached exhibits (Exhibit 99.1, 99.2, and 99.3) which are incorporated by reference but not detailed within the body of this 8-K. The filing notes that forward-looking statements regarding Adjusted EBITDA, Adjusted EBITDA margin, and the 'Rule of 40' profile are included in the referenced exhibits.
Material Changes and Executive Leadership
The most significant material changes reported are the resignation of the Chief Financial Officer and a Director, alongside the appointment of new C-suite executives:
- CFO Resignation: Bryan Hunt resigned as Chief Financial Officer and principal financial officer, effective March 1, 2024. His departure is not due to any disagreement with the company. He will serve as a senior advisor until April 1, 2024.
- Director Resignation: Mark Templeton resigned from the Board of Directors and its committees, effective March 1, 2024. His departure is also not due to any disagreement.
- New CFO Appointment: Jason Alger, currently the Chief Accounting Officer, was appointed as the new Chief Financial Officer, effective March 1, 2024. His base salary is set at $350,000 with a target annual bonus of 65%. He will receive 70,000 RSUs and 35,000 performance-based RSUs (PRSUs).
- New COO Appointment: Daniel LeSueur, currently Senior Vice President and General Manager of the Professional Services Business Unit, was appointed as Chief Operating Officer, effective March 1, 2024. His base salary is set at $360,000 with a target annual bonus of 70%. He will receive 70,000 RSUs and 35,000 PRSUs.
Compensation and Separation Arrangements
Specific financial terms were disclosed for the departing and incoming executives:
- Bryan Hunt (Outgoing CFO): Will receive a lump sum cash payment of $247,500 (representing nine months' base salary and COBRA reimbursement) within 30 days of separation. Additionally, 61,250 RSUs will accelerate, and the exercise date for certain vested options will be extended to March 1, 2025.
- Mark Templeton (Outgoing Director): The Board approved the acceleration of 13,405 RSUs that were scheduled to vest in June 2024.
- Jason Alger (Incoming CFO) & Daniel LeSueur (Incoming COO): Both executives will receive identical equity packages consisting of 70,000 RSUs (vesting 1/3rd on Dec 1, 2024, then quarterly) and 35,000 PRSUs tied to Total Shareholder Return (vs. Russell 3000), Adjusted EBITDA margin, and revenue growth rate over a three-year period.
Guidance, Outlook, and Risks
The filing incorporates by reference the company's 2024 Guidance and Updated Growth and Financial Targets. It includes standard forward-looking statement disclaimers, noting that actual results may differ materially due to risks and uncertainties. The company explicitly states it does not intend to update forward-looking statements except as required by law.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) and Exhibit 99.2 (Financial Highlights) for specific Q4 and Full Year 2023 revenue, Adjusted EBITDA, and cash flow figures.
- Verify the specific performance metrics and thresholds for the PRSUs granted to the new CFO and COO in the referenced exhibits.
- Confirm the timeline for the transition of the CFO role and the interim advisory period of Bryan Hunt.
- Assess the impact of the leadership changes on the company's stated 2024 growth targets and 'Rule of 40' profile.